INBRX-106 Clinical Trial
Part 1, single agent dose escalation, of the Phase 1 trial for INBRX-106 was completed in January 2021. Parts 2 and 3, single agent dose expansion and dose escalation in combination with Keytruda, are currently enrolling in the following tumor types:
- Solid Tumors
- Non-Small Cell Lung Cancer (NSCLC)
- Melanoma
- Head and Neck Cancer (HNSCC)
- Gastric (GIST) and Gastroesophageal Adenocarcinoma (GEA) Cancer
- Renal Cell Carcinoma (RCC)
- Urothelial (transitional) Carcinoma (TCC)